Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P080011/S204

BIOFINITY (COMFILCON A)

CooperVision, Inc. · Decision date Sep 2, 2026

MEDTECHLEDGER EXPLANATIONP080011/S204

What did the FDA decide?

The FDA recorded decision OK30 on 2026-09-02 for PMA supplement P080011/S204, associated with BIOFINITY (COMFILCON A), a soft extended-wear contact lens (product code LPM, ophthalmic specialty), held by CooperVision, Inc. The supplement was filed as a 30-Day Notice with the reason recorded as a process change affecting manufacturer, sterilizer, packager or supplier.

The recorded statement covers introduction of a new Density Meter at the Juana Diaz, Puerto Rico facility. This is a supplement-level decision about that manufacturing change, not a new approval of the BIOFINITY lens system as a whole. The source record does not describe the meter's specifications, its role in production or release testing, or any supporting data, and no documents were included, so the technical basis for OK30 cannot be assessed from this entry.

FDA approval order statement

introduction of a new Density Meter at the Juana Diaz, Puerto Rico facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P080011/S204
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P080011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P080011 · Original PMA

    BIOFINITY (COMFILCON A)

  2. P080011/S204 received

    Application receipt date recorded by FDA.

  3. P080011/S204 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P080011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P080011

Product / regulatory recordCompanyPathwayDecision dateSource
CooperVision, Inc.PMA approvalNov 19, 2008FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CooperVision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6101 Bollinger Canyon Rd., Suite 500, San Ramon, CA, 94583

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records